Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

239
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
239
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

204
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
204
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

352
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
352
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

324
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
324
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

445
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
445

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tuberculosis Prevention in Pregnant Women Living with HIV: A Review of the Current Management Strategies and Guidance.

Infection and drug resistance·2026
Same author

Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020.

Emerging infectious diseases·2026
Same author

Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial.

The lancet. HIV·2025
Same author

Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design.

Contemporary clinical trials·2025
Same author

A clinical practice guideline for tuberculous meningitis.

The Lancet. Infectious diseases·2025
Same journal

HEALTHY AGING: THE PROMISE, AND PERILS, OF GEROSCIENCE.

Transactions of the American Clinical and Climatological Association·2025
Same journal

TESTOSTERONE AND INSULIN RESISTANCE IN MEN: EVIDENCE FOR A COMPLEX BI-DIRECTIONAL RELATIONSHIP.

Transactions of the American Clinical and Climatological Association·2025
Same journal

REVISITING GLUCAGON ACTION IN DIABETES: IS IT ALL BAD?

Transactions of the American Clinical and Climatological Association·2025
Same journal

IMPLEMENTING HOME-BASED CANCER PREVENTION AND SCREENING: AN OPPORTUNITY FOR EQUITY.

Transactions of the American Clinical and Climatological Association·2025
Same journal

THE GID COMPLEX REGULATES DNA END PROCESSING DURING DNA DOUBLE-STRAND BREAK REPAIR BY NONHOMOLOGOUS END JOINING.

Transactions of the American Clinical and Climatological Association·2025
Same journal

THERAPIES FOR NEONATAL DISEASES OF THE SURFACTANT SYSTEM.

Transactions of the American Clinical and Climatological Association·2025
See all related articles

Related Experiment Video

Updated: Sep 12, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K

REVOLUTIONIZING TUBERCULOSIS REGIMEN DEVELOPMENT.

Kelly E Dooley1, Radojka Savic1

  • 1Nashville, TN.

Transactions of the American Clinical and Climatological Association
|August 7, 2025
PubMed
Summary
This summary is machine-generated.

Innovations in data integration and computational methods are accelerating tuberculosis drug development. This progress aims to deliver new treatments faster to combat the growing threat of drug-resistant tuberculosis.

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K

Related Experiment Videos

Last Updated: Sep 12, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K

Area of Science:

  • Drug Discovery and Development
  • Computational Biology
  • Infectious Diseases

Background:

  • First-line tuberculosis (TB) treatments established between the 1950s-1970s face stagnation, with recent drug approvals following lengthy development cycles and high failure rates.
  • The TB drug development pipeline is currently robust, featuring diverse new chemical entities, necessitating optimized advancement strategies.
  • Emerging resistance to existing TB drugs underscores the urgent need for novel therapeutic agents.

Purpose of the Study:

  • To explore how recent innovations in data integration and computational methods can revolutionize TB drug development.
  • To accelerate development timelines and increase the probability of success for new TB compounds.
  • To facilitate the timely approval of novel drugs to combat the global TB epidemic.

Main Methods:

  • Leveraging recent advancements in data integration techniques.
  • Applying innovative computational methods to drug discovery and development processes.
  • Analyzing the TB drug development pipeline for optimization opportunities.

Main Results:

  • Recent innovations are identified as key drivers for revolutionizing TB drug development.
  • Accelerated development timelines and heightened success probabilities are anticipated.
  • Potential for unprecedented approval timeframes for novel TB drugs.

Conclusions:

  • Data integration and computational methods offer a powerful strategy to optimize TB drug development.
  • These advancements promise to deliver new TB drugs more efficiently, addressing the challenge of drug resistance.
  • The explored strategies hold potential applicability for drug development in other medical fields.